Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC)

Bone Marrow Transplantation

Volumn 18, Issue 6, 1996, Pages 1087-1093

  Meisenberg, B R ^a,b   Miller, W E ^a   McMillan, R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

High dose chemotherapy; Peripheral blood progenitor cell transplant; Tandem cycles

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GROWTH FACTOR; MELPHALAN; MITOXANTRONE; THIOTEPA;

ADULT; AGED; ARTICLE; CANCER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; HEALTH INSURANCE; HUMAN; HUMAN CELL; KIDNEY DISEASE; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BONE MARROW TRANSPLANTATION; CARBOPLATIN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; MALE; MELPHALAN; MIDDLE AGED; MITOXANTRONE; NEOPLASMS; PATIENT ACCEPTANCE OF HEALTH CARE; REMISSION INDUCTION; SALVAGE THERAPY; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0030476555     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Williams SF, Gilewski T. Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
2. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559-2566.
3. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
4. Ayash LJ, Elias A. Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
5. Meisenberg B, Miller W, McMillan R. Lower dose cyclophosphamide (LDC) plus growth factor (GF) results in efficient and predictable mobilization (MZ) of peripheral blood progenitor cells (PBPC). Blood 1995; 86 (Suppl. 1): 988 (Abstr.).
6. Perry MC. The Chemotherapy Source Book. Williams & Wilkins: Baltimore, 1991.
7. Snedecor GW, Cochran WG. Statistical Methods, 7th edn. Iowa State University Press: Ames, 1980 pp 135-148.
8. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988; 6: 1501-1515.
9. Gianni AM, Bonadonna G. High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 1989; 25: 1027-1030.
10. Spitzer G, Adkins D, Dunphy F et al. Design of preparative regimens for stem cell transplantation in breast cancer. Breast Cancer Res Treat 1993; 26: S-3-S-9.
11. Leyvraz S, Ketterer N, Vuichard P et al. Sequential high-dose combination chemotherapy with granulocyte colony-stimulating factor and peripheral blood progenitor cells in patients with solid tumors: intensification limited by nonhemagologic toxic effects (Letter). J Natl Cancer Inst 1993; 85: 1962-1964.
12. Pittman KB, To LB, Bayly JL et al. Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transplant 1992; 10: 535-540.
13. Haas R, Mohle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3778-3794.
14. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
15. Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-128.
16. Bitran JD, Samuels B, Klein L et al. Tandem high dose in intensification chemotherapy (HDIC) in women with stage IV breast cancer: improved outcome when sequential HDIC is employed. Proc Am Soc Clin Oncol 1994; 13: 79 (Abstr.).
17. Broun ER, Sridhara R, Sledge GW et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13: 2050-2055.
18. Crown J, Kritz A, Vahdat L et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11: 1144-1149.
19. Fennelly D, Shapiro F, Schneider J et al. A novel approach to delivery of dose-dense chemotherapy (C) in patients (PTS) with advanced ovarian cancer (AOC): a phase I trial. Proc Am Soc Clin Oncol 1995; 14: 314 (Abstr.).
20. Skipper HE, Schabel FM Jr, Mellett LB et al. Implications of biochemical cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970; 54: 431-450.